Katie and Lyndsay Cooper regularly monitored their breasts since discovering they had the BRCA1 mutation. Eventually, the ...
The astrophysicist is using preimplantation genetic testing (PGT) to eliminate her future children’s risk of inheriting the ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing salpingo ...
"The benefits of RRM and RRSO have been shown for BRCA-mutation carriers without a prior history of cancer, but their impact for BRCA-mutation carriers with a history of early-onset breast cancer ...
"This global study provides the first evidence that risk-reducing surgeries improve survival outcomes among young BRCA-mutation carriers with a prior history of early-onset breast cancer," said ...
"During Breast Cancer Awareness Month, it's especially important to highlight how, by streamlining the diagnostic process for determining BRCA mutation status, we can expand access to BRCA testing ...
Patients with high-risk, BRCA-positive breast cancer who received ... to be given intermittently to eliminate cells in BRCA mutation carriers that have begun to transform toward several types ...
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Endometrial Cancer.
The Australian government announces Olaparib now available on the PBS for HER2-negative metastatic breast cancer patients with mutated BRCA1 or BRCA2 gene.
Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...
“The benefits of RRM and RRSO have been shown for BRCA-mutation carriers without a prior history of cancer, but their impact for BRCA-mutation carriers with a history of early-onset breast ...